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Objective. To evaluate the cytotoxicity of hyaluronic acid (HA) on a tissue-engineered compound for bone grafting
containing osteoblastic cells (OFCOL II), platelet-rich plasma (PRP) with or without thrombin (Thr), and hydroxyapatite (HP)
by the MTT assay.
Study Design. Studied groups were formed as follows: (A) Cells  HA  PRP with Thr  hydroxyapatite (HP); (B) Cells  HA 
PRP  HP; (C) Cells  HA  HP; (D) Cells  HP; (E) Cells  HA; (F) Cells  PRP with Thr; (G) Cells  PRP; and (H) Pure
Dulbecco’s modified Eagle’s medium (DMEM) with 15% fetal bovine serum. A 2-way ANOVA and Tukey’s test were applied
for statistical analysis (P  .05).
Results. Results of cell viability for each group were as follows: A: 79%, B: 67%, C: 68%, D: 99%, E: 74%, G: 89%, F: 90%,
and Group H: 100%.
Conclusions. Results suggested a decrease in cell viability in the presence of HA. (Oral Surg Oral Med Oral Pathol Oral
Radiol 2014;117:e423-e428)The restoration of large bone defects constitutes a sig-
nificant clinical challenge for orthopedic and dental
surgeons.1 More than 2.2 million bone graft procedures
are performed annually around the world in dental,
neurosurgical, and orthopedic fields.2 The popularity of
dental implants has prompted an even higher demand
for bone reconstruction, especially in the dentoalveolar
region.3
One of the prerequisites for oral rehabilitation in-
volving dental implants is the presence of an adequate
alveolar process, which might allow the correct place-
ment of implants to support a functional prosthesis for
a long time.4,5 Aiming to improve situations in which
this bone structure is compromised, several different
biomaterials and surgical techniques have been tested
as alternatives for alveolar bone reconstruction.2,6,7
Several disadvantages associated with the use of
some currently available biomaterials for bone grafting
have been suggested, including some related to autog-
enous bone,5 even though it has been widely considered
the biomaterial of choice for bone grafting because of
its osteoconductive and osteogenic properties.2 The in-
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for graft surgeries should be addressed carefully, how-
ever, as aspects, such as donor site morbidity and
limited material availability, may frequently constitute
a clinical inconvenience.5 Described as an attempt to
overcome these disadvantages, bone reconstructive al-
ternatives involving tissue-engineered compounds have
been considered as a promising treatment option with
great potential for clinical application in dentistry.8
Tissue engineering is the general term used to de-
scribe the production of living tissues through the ap-
plication of principles of biology and engineering, in-
volving mainly cell-culture techniques and porous
matrices.9 Different types of cells, including osteo-
blasts, may proliferate and maintain their phenotypes
when cultured first in bidimensional substrates, and
later inserted into porous matrices or tridimensional
gels,9,10 maintaining consistency and dimensional sta-
bility during early phases of bone graft healing partic-
ularly to avoid collapsing of surrounding soft tissues.
As tissue engineering evolves, many biomaterials
have been evaluated during the search for the ideal
matrix for tissue reconstruction.11 A biocompatible ma-
Statement of Clinical Relevance
Results of the present investigation suggest that the
HA matrix evaluated here might negatively influ-
ence bone cell viability in tissue-engineered graft-
ing compounds, indicating the need to further in-
vestigate the ideal structural characteristics of HA
to be used for this purpose.e423
ORAL AND MAXILLOFACIAL SURGERY OOOO
e424 Boeckel et al. June 2014terial able to maintain cell viability, and allow cell
proliferation and phenotype expression at the graft site,
with also a structural density to allow increase in tissue
volume, would constitute a major advancement for
bone grafting12; however, there is still no consensus in
the literature about the ideal biomaterial to be used in
these types of bone reconstruction.
Hyaluronic acid (HA) has been considered a possible
alternative biomaterial for tissue engineering.13 It con-
stitutes the basic component of extracellular matrix in
some organic tissues, and has been indicated as a pos-
sible cell carrier to be applied for tissue-engineered
bone reconstruction.13,14 Its reported shock-absorption
properties and low potential for allergic and/or immu-
nogenic reactions also endorse its application for this
purpose,15 although not supported by some studies that
indicated a decrease in cellular viability when HA is
applied as a matrix.16,17 In contrast to these findings,
other reports have presented even a possible increase in
cell viability associated with its use.18,19
Based on this controversy in the literature, the present
study was conducted to evaluate in vitro the possible
effects of HA as a matrix for a tissue-engineered com-
pound of cultured osteoblastic cells associated with plate-
let-rich plasma (PRP) and synthetic hydroxyapatite (HP)
by the methylthiazol tetrazolium (MTT) assay.
MATERIAL AND METHODS
This study was approved by the Research Ethics Com-
mittee of the Faculty of Dentistry of the Pontifical
Catholic University of Rio Grande do Sul (PUCRS).
Cell culture and sample preparation
An ampule containing the OFCOL II cell line was
removed from liquid nitrogen and unfrozen in a water
bath at 37°C. The cellular suspension was transferred to
a culture flask containing Dulbecco’s modified Eagle’s
medium (DMEM) with 15% fetal calf serum and 10
g/mL gentamicin in the flow hood. After adhesion of
Table I. Tested groups and the respective volumes of
Group Cells
Group A 21 L with 5  103 25
Group B 21 L with 5  103 25
Group C 21 L with 5  103 25
Group D 21 L with 5  103
Group E 21 L with 5  103 25
Group F 21 L with 5  103
Group G 21 L with 5  103
Group H (Positive control) 21 L with 5  103
DMEM, Dulbecco’s Modified Eagle’s Medium; HA, hyaluronic aci
components are not part of the respective experimental group.the cells to the culture flask, the medium was changedto eliminate residues from the freezing medium. These
remaining cells were then rinsed with dimethyl sulfox-
ide (DMSO) (Henrifarma, São Paulo, São Paulo, Bra-
zil). The OFCOL II cell cultures were incubated and
kept in a humidified atmosphere of 95% air and 5% CO2
at 37°C to maintain a 7.4 pH. Once semiconfluence was
achieved, the cells were washed with a buffered saline
solution without calcium or magnesium (CMF-PBS)
(Henrifarma, São Paulo, Brazil), trypsinized, and counted
in a Neubauer chamber. Next, the cells were cultivated
in a 96-well plate (TPP, St. Louis, MO) at a density of
5  103 cells in 15% DMEM in a volume of 21 L in
each well. The experimental and control groups were
run in quadruplicate. The cells were seeded 24 hours
before the experiment in each well, when they reached
semiconfluence (80% growth). The MTT assay was
conducted after 48 hours of cell culture added with HA,
HP, and PRP according to the groups’ division for
cellular proliferation analysis.
As shown in Table I, 1 control and 7 experimental
groups were run in quadruplicate for cellular viability
analysis by the MTT assay. Each experiment was re-
peated 3 times.
PRP preparation
For the PRP preparation, approximately 15 mL of hu-
man blood was collected in 3 different commercially
available 5-mL tubes containing 3.2% sodium citrate
(BD Vacutainer/Buff Na. Citrate—ref: 369,714; BD
Vacutainer; Sao Paulo). Using a double centrifugation
technique, the first one was performed at 400g for 10
minutes to separate the blood plasma. After this cen-
trifugation, the supernatant was removed using a sero-
logic pipette. The supernatant was placed in a second
Falcon-type tube, which was then centrifuged at 800g
for 10 minutes to concentrate the platelets. After this
second centrifugation step, the supernatant was com-
pletely removed and part of it was returned to the tube,
so that the material contained within the tube was 10%
component per well
Applied volumes
PRP HP DMEM Thrombin
12.5 L 4 mg 149 L 2.5 L
12.5 L 4 mg 151 L —
— 4 mg 164 L —
— 4 mg 189 L —
— — 164 L —
12.5 L — 174 L 2.5 L
12.5 L — 176 L —
— — 189 L —
hydroxyapatite; PRP, platelet-rich plasma; —, indicates that theseeach
HA
L
L
L
—
L
—
—
—
d; HP,of the original collected volume. The entire procedure,
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of 1.5 mL of PRP.
To obtain the autologous thrombin, we transferred
1.2 mL of the upper portion of the blood plasma col-
umn after the first centrifugation in a sterile 15-mL
Falcon tube. Next, 0.3 mL of 10% calcium gluconate
was added to the 1.2 mL of plasma with platelets and
then placed in water bath at 37°C for 15 minutes to set
the plasma into a gel state. Another centrifugation step
of 800g was performed for 10 minutes, resulting in
separation of thrombin in the tube.
The PRP gel was finally obtained through the addi-
tion of 2.5 L of autologous thrombin to 12.5 L of
PRP in a ratio of 1:5. A 1-minute waiting period was
necessary for the formation of a PRP gel in the A, B, F,
and G test groups. The volume of 12.5 L was selected
based on previous study.20
Application of HA
A total of 25 L of HA gel (Teosyal 30G Touch Up,
Teoxane, Geneva, Switzerland) containing 25 mg/mL of
HA with a pH of 7.3 was used in each culture well for the
A, B, C, and E groups. HA concentration was determined
based on the results from a concentration curve test done
in a pilot study. After an initial dilution of 25 L of
Teosyal in 100 L of 15% DMEM, we obtained a final
concentration of 2.97 mg/mL of HA applied per well.
Application of HP
A total of 4 mg of commercially available synthetic HP
(Straumann BoneCeramic Biora AB, Malmö, Switzer-
land) composed of 60% HA and 40% -tricalcium
phosphate (-TCP), presenting a pore size of 100 to
500 m was weighed and placed in each culture well
(TPP) of the A, B, C, and D groups. The HP content
was exposed to ultraviolet light for 20 minutes before
its addition to the cultures for sterilization.
Cell viability assay (MTT)
The MTT assay was conducted here to assess cell
viability, aiming to evaluate the ability of live osteo-
blastic cells to reduce 3-(4.5-dimethyl-2-thiazole)-2.5-
diphenyl-2-yl-tetrazolium bromide (Acros Organics,
Morris Plains, NJ) and form insoluble violet formazan
crystals. After each cell group establishment, a 10%
MTT solution (5 mg/mL) diluted in PBS was added to
each well. The cultures were immediately incubated for
2 hours at 37°C and protected from light until the
presence of the violet formazan crystals was observed.
For formazan crystals, solubilization, 100 L of DMSO
was added to each well. Later, the absorbance at a
wavelength of 570 nm (Microplate Reader, SpectraMax
M 5, ’EUA; Molecular Devices, Sunnyvale, CA) wasrecorded and analyzed using the Softmax Pro 5.2 pro-
gram (Molecular Devices).
Statistical analysis
All results were expressed as mean  SD. A compar-
ative analysis of means was performed using the anal-
ysis of variance (ANOVA) and Tukey’s multiple com-
parisons test (P  .05).
RESULTS
The optical density (OD) values indicated a percentage
of viable cells compared with the control group (H),
which was considered 100% viable.
According to these results, a significant difference
was observed between groups B and C in comparison
with group H (P  .05). No significant difference was
observed between groups A, D, E, F, and G in com-
parison with group H (P  .05).
Group B (with 67% viability) and group C (with 68%
viability) were the groups with HA that exhibited the
lowest viabilities. The viabilities of these 2 groups were
similar but differed significantly from that of group D
(cells  HP), which presented the greatest viability at 99%.
Group A (cells  HA  PRP with thrombin  HP) with
79% cellular viability, group E (cells  AH) with 74%
viability, group F (cells  PRP with thrombin) with 90%
viability, and group G (cells PRP) with 89% viability did
not differ statistically from each other (P  .05) (Fig. 1).
DISCUSSION
As significant differences in cell viability were verified
among the studied groups, it might be important to
analyze individually the possible influence of HA, PRP,
human thrombin, and HP on the obtained cell viability
results.
To our knowledge, studies evaluating the use of HA
as a matrix applicable to bone grafting involving tissue-
engineering techniques are limited. Therefore, the pres-
ent study aimed to evaluate the viability of osteoblastic
cells in the presence of this material. Also, it is clear
that there is no consensus in the current literature re-
garding the ideal formulation of HA as to its structural
constitution and/or ideal concentration. Some studies
reported a decrease in cellular viability when HA was
used,16,17 whereas others indicated opposite results.18,19
Previous studies involving bone tissue engineering sug-
gested the need for a material that might act as a vehicle
capable of transporting and maintaining bone cells to
the grafted site, ensuring the tissue volumetric increase
necessary for bone reconstruction.12 Because of its
characteristics, HA may act as a plasticizing agent for
tissue-engineered graft compounds by combining min-
eral matrices and cultured cells into a gel-like compos-
ite easily handled during surgeries, and keep its con-
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avoid collapsing of surrounding tissues during early
stages of bone healing.21 Although not evaluated here,
these advantages might help to achieve a better clinical
response of tissue-engineered bone grafts compared
with the traditional techniques currently available.
The cytotoxicity of the HA, teosyal, which has been
said to present similar composition as the HA in living
tissues, was tested on OFCOL II osteoblastic cells. The
term cytotoxicity is used here to describe the chain of
molecular events that interfere in cell molecular syn-
thesis, causing cellular dysfunction and/or its structural
damage.22 The present investigation aimed to verify if
HA might constitute an applicable vehicle with some
required characteristics desired to biocompatible matri-
ces, such as being synthetic, resorbable, fully biocom-
patible,23 nonallergenic, and nonimmunogenic.24,25
The decrease in cellular viability verified in the pres-
ence of HA might indicate a possible inhibitory effect
on the cells of the studied groups. Based on these
results, it might be speculated that the cell viability
reduction verified here could be related not to HA
chemical composition, but to the molecular weight of
the applied acid.26-28
Some studies applying HA with high molecular weight
(1000 kDa) at concentrations ranging between 50
g/mL and 1 mg/mL reported a clear stimulation of
chondrocyte,19 fibroblast,18 and melanoma29 production
in vitro. Others, though, have reported that application of
high molecular weight HA might inhibit proliferation
of fibroblasts,16 keratinocytes,17 ovarian cells,30 tendon
cells,31,32 and macrophages33 in cultures.
Similar to other in vitro studies that investigated osteo-
blastic cells and high molecular weight HA (1000
kDa), the present study also suggested a possible inhi-
Fig. 1. Cell viability of each group, expressed in percentage
groups.bition of cell proliferation, which was not observed inother investigations that analyzed low molecular
weight HA (50 kDa).26,27
Furthermore, an HA concentration of 2.97 mg/mL
was applied to all HA groups, which was determined
based on results of a concentration curve test done in an
earlier pilot study. This concentration was higher than
those recommended by Kawasaki et al.,19 Yoneda et
al.,18 and Ahrens et al.29 Although the HA concentra-
tion applied here was determined by a concentration
curve in a pilot study, it differed from the recommen-
dations of these studies that failed to describe specifi-
cally how it was calculated. Further investigations
might be necessary to establish the ideal HA concen-
tration to be applied in tissue-engineered graft com-
pounds in vivo and its possible effects on bone cell
proliferation and differentiation.
The HA influence on bone cells cultured in the
absence of hyaluronidase enzyme is another relevant
issue present here to be discussed. This absence could
lead to some inconveniences to the cell metabolism,
allowing the HA molecule in its natural state to act in
close contact with cells for a longer time, and most
likely inhibiting the natural processes of cell prolifera-
tion and differentiation. With the HA degradation
through the addition of hyaluronidase to the experi-
ment, smaller acid molecules would be in contact with
the cells and possibly induce a more favorable environ-
ment for cell division and differentiation as well as a
possible activation of the cell-signaling chain linked to
inflammatory response.34
In the present study, human PRP was added to some
analyzed groups aiming to positively influence cell
differentiation and induce an increased cellular viability
(74% in group E [cells  HA] and 79% in group A
[cells HA PRP with thrombin HP]). In a similar
rent letters indicate statistical differences (P  .05) between. Diffestudy, Kim et al.13 found 72% viability of mesenchy-
OOOO
Volume 117, Number 6 Boeckel et al. e427mal human stem cells with high molecular weight HA
(170,000 Da) in the same period, without the addition
of specific growth factors. However, when bone mor-
phogenetic protein-2 was added to the HA gel, cellular
viability increased to 81%.
PRP is a well-known source of growth factors that
play an important role in cell proliferation and differ-
entiation processes, such as platelet-derived growth
factor, transforming growth factor-, and insulin-like
growth factor-1.35 Also, human thrombin was added in
group A (cells  HA  PRP with thrombin  HP) and
group F (cells  PRP with thrombin) for platelet acti-
vation, and a small improvement in cellular viability
was observed within these groups. However, these re-
sults were not statistically significant when compared to
the nonthrombin groups.
In similar studies, Krasna et al.21 and Arpornmaek-
long et al.36 tested the effects of the application of PRP
in vitro on the proliferation of human fibroblastic cells.
In both studies, the highest PRP concentrations (ap-
proximately 20%) exhibited better responses by the
MTT assay, indicating that PRP cellular stimulation is
dose-dependent. These findings directly influenced the
determination of the final volume of PRP applied to the
OFCOL II cells in the present study.
The advantages of PRP applied to cell cultures have
been observed in different investigations.21,36 In the
present study, group F (cells PRP with thrombin) and
group G (cells  PRP) showed higher cell viability
compared with other groups with HA. When compared
with control group, however, PRP alone was not able to
act as an influential agent to improve cellular prolifer-
ation.
Regarding the presence of HP, a positive result in
cell proliferation was verified, obtaining 99% viability
in group D (cells  HP). Group C (cells  HA  HP)
presented one of the lowest cellular viabilities, suggest-
ing that HP might not have interfered or contributed
with the inhibitory effect verified in HA groups.
The present findings were obtained from an in vitro
evaluation, which undoubtedly presents some limita-
tions. On the topic of tissue engineering, in vitro studies
do not allow the exact reproduction of a living tissue
environment, which involves among other things appli-
cation of forces by the musculoskeletal system, which
is an important player on the physiological induction of
bone formation.10 Kim et al.13 reported marked differ-
ences when comparing results from HA applications
both in vitro and in vivo, stating that the in vivo
findings were significantly better in terms of bone for-
mation outcome.
Even considering that the present study indicated an
acceptable average of cell viability of 72% in the pres-
ence of HA, additional in vivo studies may be needed toconfirm its indication in bone tissue engineering.
Changes in the HA molecular weight might be tested to
achieve even more expressive cell viability percent-
ages. Hence, other aspects to be investigated might
include the addition of other esters to the HA formula
and/or fracturing of the HA molecule to possibly im-
prove its structural characteristics while maintaining its
viscoelasticity and biological functions.
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